Drug Profile


Alternative Names: GC-1008

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Genzyme Corporation
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fibrosis; Malignant melanoma; Pulmonary fibrosis; Renal cancer
  • Discontinued Focal segmental glomerulosclerosis

Most Recent Events

  • 27 Feb 2017 Baylor College of Medicine in collaboration with Genzyme, Shriners Hospitals for Children, Hugo W. Moser Research Institute, Hospital for Special Surgery, University of California, University of Nebraska, Oregon Health and Science University and University of South Florida plans a phase I trial for Osteogenesis imperfecta in USA (NCT03064074)
  • 15 Dec 2016 Biomarkers information updated
  • 16 Oct 2015 National Cancer Institute plans a phase I/II trial for Non-small cell lung cancer in USA (NCT02581787)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top